Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat in early pulmonary vascular disease
2021-001633-40Phase 2Active
- Sponsor
- Thoraxklinik am Universitätsklinikum Heidelberg
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary vascular disease (PVD) and pulmonary arterial hypertension (PAH) comparing Riociguat with Placebo (2 arms). Primary endpoint: Change in pulmonary vascular resistance. Started Dec 2021; status: active.
02
Drugs
riociguat
03
Conditions
pulmonary vascular disease (PVD)pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2021-001633-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001633-40.